Milestone Pharmaceuticals to Announce Fourth Quarter and Full-Year 2025 Financial Results on March 20, 2026
Rhea-AI Summary
Milestone Pharmaceuticals (Nasdaq: MIST) will report its fourth quarter and full-year 2025 results and provide a business update on Friday, March 20, 2026 before the market opens. A conference call and webcast for investors is scheduled at 8:30am ET.
Access details include domestic and international dial‑in numbers, a conference ID, a Call me™ option active 15 minutes before start, and a replay available on the company’s Investors and Media website.
Positive
- None.
Negative
- None.
News Market Reaction – MIST
On the day this news was published, MIST gained 2.34%, reflecting a moderate positive market reaction. This price movement added approximately $3M to the company's valuation, bringing the market cap to $146M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
MIST fell 3.93% while peers were mixed: ACOG +0.34%, VTYX +0.07%, CYBN +0.12%, GLSI -2.96%, KYTX -4.66%. No coordinated sector move flagged.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Feb 26 | Conference appearance | Neutral | -0.6% | TD Cowen healthcare conference webcast and investor presentation details. |
| Feb 10 | Leadership change | Positive | +1.1% | Appointment of new General Counsel tied to CARDAMYST commercial launch. |
| Feb 03 | Equity inducement grants | Neutral | +0.5% | Stock option inducement grants to new employees under listing rule 5635(c)(4). |
| Jan 26 | Product launch | Positive | -2.0% | U.S. commercial availability of CARDAMYST nasal spray for PSVT. |
| Jan 06 | Regulatory milestone | Positive | +1.5% | EMA acceptance of MAA for etripamil nasal spray (TACHYMIST) in PSVT. |
Recent news has mostly seen price moves align with the tone of announcements, with one notable divergence on a positive U.S. launch update.
Over the last few months, Milestone issued several operational updates, including EMA acceptance of an etripamil MAA on Jan 6, 2026, U.S. availability of CARDAMYST on Jan 26, 2026, and multiple equity grants and inducement awards in early February. It also announced a new General Counsel alongside CARDAMYST’s commercial launch on Feb 10, 2026 and a conference appearance on Feb 26, 2026. Today’s earnings date notice follows this commercialization and regulatory ramp-up and sets expectations for fuller financial disclosure.
Market Pulse Summary
This announcement sets March 20, 2026 as the date for Milestone’s fourth quarter and full-year 2025 results, alongside a business update. Investors will likely focus on early revenue traction for CARDAMYST, progress following EMA MAA acceptance, and any updated commercial or regulatory plans. Given recent insider equity activity and commercialization milestones, the call at 8:30am ET provides a key checkpoint for evaluating execution and capital needs.
AI-generated analysis. Not financial advice.
Conference Call and Webcast Scheduled for Friday, March 20 at 8:30am ET
MONTREAL and CHARLOTTE, N.C., March 12, 2026 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST) today announced that it will report fourth quarter and full-year 2025 results and provide a business update on Friday, March 20, 2026, before the market opens. The announcement will be followed by a conference call and webcast for investors at 8:30am ET.
| Conference Details: | |
| Conference Dial-in: | 1-877-407-0792 |
| International Dial-in: | 1-201-689-8263 |
| Conference ID: | 13759195 |
| Webcast link: | click here |
Call me™: Participants can use Guest dial-in numbers above and be answered by an operator OR click the Call me™ link for instant telephone access to the event. The Call me™ link will be made active 15 minutes prior to scheduled start time.
A replay of the audio webcast of the call will be available under the “Investors and Media” section of Milestone's corporate website, www.milestonepharma.com.
About Milestone Pharmaceuticals
Milestone Pharmaceuticals Inc. (Nasdaq: MIST) is a biopharmaceutical company developing and commercializing innovative cardiovascular medicines to benefit people living with certain heart conditions. Milestone’s lead product is CARDAMYST™ (etripamil) nasal spray, a novel calcium channel blocker, which is FDA approved for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults. Etripamil is also in development for the control of symptomatic episodic attacks associated with AFib-RVR.
Contact:
Investor Relations
Kevin Gardner, kgardner@lifesciadvisors.com
Media Relations
Rebecca Novak, rnovak@milestonepharma.com
FAQ
When will Milestone (MIST) report fourth quarter and full-year 2025 results?
How can investors join the Milestone (MIST) March 20, 2026 conference call and webcast?
What is the conference ID for Milestone (MIST) investor call on March 20, 2026?
Will Milestone (MIST) provide a replay of the March 20, 2026 earnings webcast?
What time should investors log on for the Milestone (MIST) March 20, 2026 Call me™ option?
Where can I find materials or slides from Milestone (MIST) following the March 20, 2026 update?
